CXCR3 and Patent ductus arteriosus: To assess the requirement for Cxcr3 on 1045 T cell infiltration into PDA, 1045 T cells were transferred into mice bearing established and poorly immunogenic (CB-) KPC2 orthotopic tumors [8] using a similar therapy protocol that has efficacy in autochthonous KPC PDA [7] with or without anti-Cxcr3 (Fig. 6F).